Centiva Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Centiva Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,112	Closed	-$77K	–	1630
2021 Q3	$77K	Buy	+10,112	New	+$85.7K	﹤0.01%	1091

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Centiva Capital's SRNE Position: Q4 2021 in Review

Centiva Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 10,112 shares — an estimated $77K sold.

Centiva Capital first reported a position in SRNE in Q3 2021 and held it in 1 quarter. The position peaked at $77K in Q3 2021. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

Centiva Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Centiva Capital sold 10,112 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $77K.
Centiva Capital first reported a position in Sorrento Therapeutics, Inc. in Q3 2021 and held it in 1 quarter.
Centiva Capital's Sorrento Therapeutics, Inc. position peaked at $77K in Q3 2021.
234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.